Given the promising results of DDC in inhibiting SOD1 and its potential implications for cancer therapy, including HBV‐related HCC, this study explores the combination of sorafenib and DDC as a therapeutic regimen. The gene discussed is SOD1; the disease is hepatocellular carcinoma.